



Tumor Immune Microenvironment in Lymphoproliferative Syndromes

Guest Editors:

Dr. Margarita Sánchez-Beato

Lymphoma Research Group,
Clinical Oncology Department,
Instituto de Investigación
Sanitaria Puerta de Hierro-
Segovia de Arana (IDIPHISA). c/
Joaquín Rodrigo 2.
Majadahonda, 28222 Madrid,
Spain

Dr. Luis De la Cruz-Merino

Clinical Oncology Department,
Virgen Macarena University
Hospital. Medicine Department,
Universidad de Sevilla. Avda Dr
Fedriani s/n, 41009 Seville, Spain

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editors

Dear Colleagues,

Lymphoproliferative syndromes constitute an extensive and heterogeneous group of oncological diseases with different features, biological behavior, and clinical evolution. The precise molecular characterization of lymphomas is gaining in interest and relevance, as it may represent the first step in the design a successful therapeutic strategy to keep disease under control. However, the complexity of lymphomas goes beyond the molecular abnormalities of malignant lymphocytes. The specific surrounding tumor microenvironment (TME) has been revealed as a factor of paramount relevance, that in some cases harbors prognostic and predictive information which can be crucial from a clinical perspective, as the availability of different types of immunotherapies has dramatically increased in the last few years.

In this Special Issue, reputed basic and clinical experts in the lymphoma field will try to thoroughly describe the specific immune TME in these diseases, from different angles, in order to identify potential new therapeutic targets that could ameliorate clinical outcomes in patients with lymphoproliferative syndromes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)